Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 8/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Theofibrate SCHEMBL49272 | 0.89 | ADORA2B (0.60) | LMNAADORA2BRXFP1ALDH1A1MAPK1 | |
| Theofibrate SCHEMBL3960649 | 0.89 | ADORA2B (0.60) | LMNAADORA2BRXFP1ALDH1A1MAPK1 | |
| Etofylline Nicotinate SCHEMBL1649975 | 0.79 | ADORA2B (0.64) | LMNAADORA2BRXFP1ALDH1A1MAPK1 | |
| Etofylline SCHEMBL27405019 | 0.78 | LMNA (0.70) | LMNAADORA2BRXFP1ALDH1A1MAPK1 | |
| SCHEMBL10963461 | 0.76 | LMNA (0.58) | LMNAADORA2BRXFP1ALDH1A1MAPK1 | |
| SCHEMBL11460190 | 0.76 | OPRK1 (0.55) | LMNAADORA2BRXFP1ALDH1A1MAPK1 | |
| SCHEMBL11883059 | 0.74 | LMNA (0.52) | LMNAADORA2BRXFP1ALDH1A1MAPK1 | |
| Etofibrate SCHEMBL29801484 | 0.73 | L3MBTL1 (0.55) | LMNAALDH1A1SMN1; SMN2 | |
| Etofibrate SCHEMBL3122 | 0.73 | L3MBTL1 (0.55) | LMNAALDH1A1SMN1; SMN2 | |
| Etofibrate SCHEMBL8168409 | 0.73 | L3MBTL1 (0.55) | LMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110251519-A | The purposes of DPP IV inhibitor | 勃林格殷格翰国际有限公司 | 2019-09-20 | — | — | CN | disclosed |
| CN-110227078-A | The purposes of DPP IV inhibitor | 勃林格殷格翰国际有限公司 | 2019-09-13 | — | — | CN | disclosed |
| CN-110075098-A | Purposes of the Li Gelieting in heart and protection renal antidiabetic treatment | 勃林格殷格翰国际有限公司 | 2019-08-02 | — | — | CN | disclosed |
| CN-109700814-A | The treatment of diabetes pair although using oral or non-oral antidiabetic medicine treatment in the still insufficient patient of glycemic control | 勃林格殷格翰国际有限公司 | 2019-05-03 | — | — | CN | disclosed |
| CN-108635355-A | The purposes of DPP IV inhibitor | 勃林格殷格翰国际有限公司 | 2018-10-12 | — | — | CN | disclosed |
| CN-108042543-A | The treatment of diabetes pair although treated using oral or parenteral antidiabetic medicine in the still insufficient patient of glycemic control | 勃林格殷格翰国际有限公司 | 2018-05-18 | — | — | CN | disclosed |
| CN-107961377-A | Combination treatment | 勃林格殷格翰国际有限公司 | 2018-04-27 | — | — | CN | disclosed |
| CN-104013627-B | For treating the DPP IV inhibitor of NASH disease | 勃林格殷格翰国际有限公司 | 2018-01-12 | — | — | CN | disclosed |
| CN-107252430-A | The purposes of DPP IV inhibitor | 勃林格殷格翰国际有限公司 | 2017-10-17 | — | — | CN | disclosed |
| CN-107115530-A | Gene diabetes mellitus type utilizes the treatment of DPP IV inhibitor such as BI 1356 | 勃林格殷格翰国际有限公司 | 2017-09-01 | — | — | CN | disclosed |
| CN-107028924-A | Pharmaceutical composition comprising BI 1356 and melbine | 勃林格殷格翰国际有限公司 | 2017-08-11 | — | — | CN | disclosed |
| CN-106975074-A | Treating diabetes | 勃林格殷格翰国际有限公司 | 2017-07-25 | — | — | CN | disclosed |
| CN-102596191-B | pharmaceutical composition comprising BI-1356 and metformin | 勃林格殷格翰国际有限公司 | 2016-12-21 | — | — | CN | disclosed |
| CN-106177958-A | Comprise DPP 4 inhibitor (BI 1356) and optionally combine the antidiabetic medicine of other antidiabetic drug | 勃林格殷格翰国际有限公司 | 2016-12-07 | — | — | CN | disclosed |
| CN-106109469-A | The anti-diabetic treatment of protection blood vessel and cardioprotection | 贝林格尔·英格海姆国际有限公司 | 2016-11-16 | — | — | CN | disclosed |
| CN-103338760-B | Anti-diabetic therapy for protecting blood vessels and protecting the heart | 贝林格尔.英格海姆国际有限公司 | 2016-08-17 | — | — | CN | disclosed |